+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Checkpoint Inhibitors"

Blood Cancer Therapeutics - Global Strategic Business Report - Product Thumbnail Image

Blood Cancer Therapeutics - Global Strategic Business Report

  • Report
  • November 2026
  • 291 Pages
  • Global
From
Esophageal Cancer Drugs - Global Strategic Business Report - Product Thumbnail Image

Esophageal Cancer Drugs - Global Strategic Business Report

  • Report
  • November 2026
  • 269 Pages
  • Global
From
MEK Inhibitors - Global Strategic Business Report - Product Thumbnail Image

MEK Inhibitors - Global Strategic Business Report

  • Report
  • November 2026
  • 132 Pages
  • Global
From
From
Gynecological Cancer Drugs - Global Strategic Business Report 2026 - Product Thumbnail Image

Gynecological Cancer Drugs - Global Strategic Business Report 2026

  • Report
  • November 2026
  • 181 Pages
  • Global
From
Immuno-Oncology - Global Strategic Business Report 2026 - Product Thumbnail Image

Immuno-Oncology - Global Strategic Business Report 2026

  • Report
  • November 2026
  • 246 Pages
  • Global
From
From
Sarcoma Drugs - Global Strategic Business Report 2026 - Product Thumbnail Image

Sarcoma Drugs - Global Strategic Business Report 2026

  • Report
  • November 2026
  • 126 Pages
  • Global
From
Urothelial Cancer Drugs - Global Strategic Business Report 2026 - Product Thumbnail Image

Urothelial Cancer Drugs - Global Strategic Business Report 2026

  • Report
  • November 2026
  • 126 Pages
  • Global
From
Cancer Immunotherapy - Global Strategic Business Report - Product Thumbnail Image

Cancer Immunotherapy - Global Strategic Business Report

  • Report
  • November 2026
  • 291 Pages
  • Global
From
From
Antineoplastic Agents - Global Strategic Business Report - Product Thumbnail Image

Antineoplastic Agents - Global Strategic Business Report

  • Report
  • November 2026
  • 183 Pages
  • Global
From
Immunotherapy Drugs - Global Strategic Business Report 2026 - Product Thumbnail Image

Immunotherapy Drugs - Global Strategic Business Report 2026

  • Report
  • November 2026
  • 233 Pages
  • Global
From
Liver Cancer Drugs - Global Strategic Business Report - Product Thumbnail Image

Liver Cancer Drugs - Global Strategic Business Report

  • Report
  • November 2026
  • 391 Pages
  • Global
From
Cancer Therapies - Global Strategic Business Report - Product Thumbnail Image

Cancer Therapies - Global Strategic Business Report

  • Report
  • November 2026
  • 590 Pages
  • Global
From
From
From
From
Loading Indicator

The Checkpoint Inhibitors market is a subset of the Oncology Drugs market, which focuses on treatments for cancer. Checkpoint Inhibitors are a type of immunotherapy, which works by blocking certain proteins that act as “checkpoints” in the body’s immune system. By blocking these checkpoints, the body’s immune system is able to recognize and attack cancer cells. This type of therapy has been found to be effective in treating a variety of cancers, including melanoma, non-small cell lung cancer, and bladder cancer. The Checkpoint Inhibitors market is highly competitive, with many companies developing and marketing their own products. Some of the major players in the market include Merck, Bristol-Myers Squibb, Roche, AstraZeneca, and Pfizer. Show Less Read more